|
시장보고서
상품코드
2102452
ACE 저해제 시장 규모, 점유율 및 성장 분석 : 약제 유형별, 적응증별, 제형별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Ace Inhibitors Market Size, Share, and Growth Analysis, By Drug Type (Benazepril, Captopril), By Indication, By Dosage Form, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 ACE 저해제 시장 규모는 2024년에 197억 달러로 평가되며, 2025년 203억 2,000만 달러에서 2033년까지 260억 2,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 3.14%로 성장할 것으로 전망되고 있습니다.
ACE 억제제 시장은 당뇨병이나 만성 신장병 등의 동반 질환을 효과적으로 관리하는 병용 요법에 대한 수요 증가를 주요 원동력으로 삼아, 인상적인 성장을 달성하고 있습니다. 의료 종사자들은 환자의 복약 순응도를 높이기 위해 1정 투여 요법을 점점 더 선호하고 있으며, 이에 따라 각 제약사는 ACE 억제제를 이뇨제, 칼슘 채널 차단제, 나트륨-포도당 공동수송체 2(SGLT2) 억제제와 병용하도록 하고 있습니다. 이러한 전략은 제품 혁신을 촉진할 뿐만 아니라 특허 기간 연장으로도 이어집니다. 또한 AI를 활용한 신약 개발의 도입으로 표적 식별이 신속해지고 개발 비용이 절감됨에 따라 시장 상황은 크게 변화하고 있습니다. 기계학습을 활용하는 기업은 새로운 억제제 후보 물질을 성공적으로 발굴해 내고 있으며, 그 결과 차세대 ACE 억제제 파이프라인이 확대되고 있습니다. 이러한 혁신은 투자자들의 관심을 끌고 있으며, 새로운 심혈관계 의약품의 시장 출시를 가속화하고 있습니다.
전 세계 ACE 억제제 시장의 성장 요인
전 세계에서 고혈압 및 심부전의 유병률이 증가하고 있는 것이 효과적인 혈압 관리 솔루션에 대한 수요를 크게 부추기고 있으며, ACE 억제제는 기본적인 치료제 카테고리로서의 입지를 확고히 하고 있습니다. 의료 전문가들은 입증된 효능과 우수한 안전성 프로파일을 바탕으로 이러한 약물을 선호하고 있으며, 그 결과 1차 의료 및 전문 의료 분야 모두에서 처방량이 증가하고 있습니다. 인구 고령화와 동반 질환 발생률 증가에 따라 ACE 억제제는 치료 프로토콜에 점점 더 많이 포함되고 있으며, 이는 시장 범위를 확대하고 지속적인 성장을 보장하고 있습니다. 또한 정기적인 혈압 모니터링에 중점을 둔 지속적인 공중보건 정책이 조기 진단과 ACE 억제제 치료의 적시 시작에 기여하고 있습니다.
전 세계 ACE 억제제 시장의 제약 요인
전 세계 ACE 억제제 시장은 주로 주요 관할권에서 일반적인 복잡하고 엄격한 규제 승인 절차로 인해 큰 제약을 받고 있습니다. 이러한 엄격한 승인 절차에서는 신규 후보 약물의 안전성과 유효성을 입증하기 위해 광범위한 임상적 증거가 요구되며, 제조사들은 다양한 규제 요건을 충족하기 위해 막대한 자원을 투입해야만 합니다. 이러한 과제는 제품 출시 지연 및 개발 비용 증가로 이어져, 혁신적인 제제에 대한 투자를 주저하게 할 가능성이 있습니다. 이러한 상황은 기존 수요가 있음에도 불구하고 궁극적으로 차별화된 치료법의 제공을 제한하고 시장 전체의 성장을 저해하게 됩니다. 또한 시판 후 조사 의무는 규정 준수 측면에서 추가적인 과제를 야기하여, 이 분야에서 사업을 운영하는 기업이 시장에 신속하게 진입하는 것을 어렵게 만들고 있습니다.
전 세계 ACE 억제제 시장 동향
전 세계 ACE 억제제 시장은 바이오시밀러의 부상으로 인해 변혁적인 변화를 겪고 있으며, 이는 경쟁 구도를 일신하고 가격 경쟁을 촉진하고 있습니다. 각 제약사가 개발 비용 절감과 규제 절차의 효율화를 활용함에 따라 저가 바이오시밀러 대체제의 도입이 점점 더 보편화되고 있습니다. 이러한 동향은 비용을 절감하면서 만성 심혈관 질환 관리를 목표로 하는 의료 제공자들의 채택 확대를 촉진하고 있으며, 궁극적으로는 신흥 경제국 환자들에게 필수 치료에 대한 접근성을 개선하는 결과로 이어지고 있습니다. 이에 반해 기존 기업은 바이오시밀러의 시장 침투율 증가와 치료 전략의 진화 속에서 시장 지위를 유지하기 위해 포트폴리오 최적화와 전략적 제휴 구축에 주력하고 있습니다.
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 ACE 저해제 시장 규모 : 약제 유형별
세계의 ACE 저해제 시장 규모 : 적응증별
세계의 ACE 저해제 시장 규모 : 제형별
세계의 ACE 저해제 시장 규모 : 유통 채널별
세계의 ACE 저해제 시장 규모 : 최종사용자별
세계의 ACE 저해제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSAGlobal Ace Inhibitors Market size was valued at USD 19.7 Billion in 2024 and is poised to grow from USD 20.32 Billion in 2025 to USD 26.02 Billion by 2033, growing at a CAGR of 3.14% during the forecast period (2026-2033).
The ACE inhibitors market is experiencing significant growth driven primarily by the rising demand for combination therapies that effectively manage comorbid conditions like diabetes and chronic kidney disease. Healthcare providers are increasingly favoring single-pill regimens to enhance patient adherence, prompting manufacturers to combine ACE inhibitors with diuretics, calcium-channel blockers, and sodium-glucose cotransporter-2 inhibitors. This strategy not only fosters product innovation but also extends patent durations. Additionally, the integration of AI-driven drug discovery is transforming the landscape by expediting target identification and reducing development costs. Companies utilizing machine learning are successfully generating novel inhibitor candidates, consequently increasing the pipeline of next-generation ACE inhibitors. This innovation is attracting investor interest and facilitating quicker market entry for new cardiovascular drugs.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ace Inhibitors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Ace Inhibitors Market Segments Analysis
Global ace inhibitors market is segmented by drug type, indication, dosage form, distribution channel, end user and region. Based on drug type, the market is segmented into Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Perindopril, Quinapril, Ramipril, Trandolapril and Others. Based on indication, the market is segmented into Hypertension, Heart Failure, Myocardial Infarction, Chronic Kidney Disease (CKD), Diabetic Nephropathy and Others. Based on dosage form, the market is segmented into Tablets, Capsules, Oral Solution and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Cardiology Clinics, Ambulatory Surgical Centers (ASCs) and Homecare Settings. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Ace Inhibitors Market
The rising prevalence of hypertension and heart failure worldwide significantly fuels the demand for effective blood pressure management solutions, establishing ACE inhibitors as a fundamental therapeutic category. Healthcare providers favor these agents due to their demonstrated efficacy and favorable safety profiles, leading to increased prescriptions in both primary and specialized healthcare settings. As the population ages and the incidence of comorbidities grows, ACE inhibitors are increasingly integrated into treatment protocols, broadening the market scope and ensuring ongoing growth. Additionally, continuous public health initiatives focusing on regular blood pressure monitoring contribute to earlier diagnoses and the timely initiation of ACE inhibitor therapy.
Restraints in the Global Ace Inhibitors Market
The Global Ace Inhibitors market faces significant constraints primarily due to the complex and demanding regulatory approval processes prevalent in major jurisdictions. These rigorous pathways necessitate extensive clinical evidence to validate the safety and efficacy of new candidates, compelling manufacturers to dedicate substantial resources to navigate diverse regulatory requirements. Such challenges can lead to delays in product launches and escalate development costs, which may dissuade investment in innovative formulations. This situation ultimately restricts the availability of differentiated therapies and impairs overall market growth, even in the face of existing demand. Additionally, the obligation for post-marketing surveillance imposes further compliance challenges, complicating rapid market entry for companies operating in this sector.
Market Trends of the Global Ace Inhibitors Market
The global ACE inhibitors market is experiencing a transformative shift due to the rise of biosimilars, which are reshaping competitive dynamics and fostering price competition. As manufacturers capitalize on reduced development costs and streamlined regulatory processes, the introduction of lower-priced biosimilar alternatives is becoming more prevalent. This trend is promoting broader adoption among healthcare providers who seek to manage chronic cardiovascular diseases while controlling costs, ultimately improving patient access to essential treatments in emerging economies. In response, established companies are focusing on portfolio optimization and forging strategic partnerships to maintain their market positions amid increased biosimilar penetration and evolving therapeutic strategies.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Ace Inhibitors Market Size by Drug Type & CAGR (2026-2033)
- Market Overview
- Benazepril
- Captopril
- Enalapril
- Fosinopril
- Lisinopril
- Perindopril
- Quinapril
- Ramipril
- Trandolapril
- Others
Global Ace Inhibitors Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Hypertension
- Heart Failure
- Myocardial Infarction
- Chronic Kidney Disease (CKD)
- Diabetic Nephropathy
- Others
Global Ace Inhibitors Market Size by Dosage Form & CAGR (2026-2033)
- Market Overview
- Tablets
- Capsules
- Oral Solution
- Others
Global Ace Inhibitors Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Ace Inhibitors Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Cardiology Clinics
- Ambulatory Surgical Centers (ASCs)
- Homecare Settings
Global Ace Inhibitors Market Size & CAGR (2026-2033)
- North America (Drug Type, Indication, Dosage Form, Distribution Channel, End User)
- US
- Canada
- Europe (Drug Type, Indication, Dosage Form, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Type, Indication, Dosage Form, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Type, Indication, Dosage Form, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Type, Indication, Dosage Form, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr Reddy's Laboratories Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals PLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Glenmark Pharmaceuticals Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alkem Laboratories Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
